• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

变应原激发后哮喘患者诱导痰中纤溶酶原激活物抑制剂-1(PAI-1)和尿激酶型纤溶酶原激活物(uPA)的浓度。

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.

作者信息

Kowal Krzysztof, Moniuszko Marcin, Zukowski Sebastian, Bodzenta-Lukaszyk Anna

机构信息

Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.

出版信息

Folia Histochem Cytobiol. 2010 Dec;48(4):518-23. doi: 10.2478/v10042-010-0075-2.

DOI:10.2478/v10042-010-0075-2
PMID:21478092
Abstract

Urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) are involved in tiisue remodeling and repair processes associated with acute and chronic inflammation. The aim of the study was to evaluate the effect of allergen challenge on concentration of uPA and PAI-1 in induced sputum of house dust mite allergic asthmatics (HDM-AAs). Thirty HDM-AAs and ten healthy persons (HCs)were recruited for the study. In 24 HDM-AAs bronchial challenge with Dermatophagoides pteronyssinus (Dp) and in 6 HDM-AAs sham challenege with saline were performed. In HDM-AAs sputum was induced 24 hours before (T0) and 24 hours (T24) after the challenge. Concentration of uPA and PAI-1 in induced sputum were determined using immunoenzymatic assays. At T0 in HDM-AAs mean sputum uPA (151 ± 96 pg/ml) and PAI-1 (4341 ± 1262 pg/ml) concentrations were higher than in HC (18.8 ± 6.7 pg/ml; p=0.0002 and 596 ± 180 pg/ml; p<0.0001; for uPA and PAI-1 respectively). After allergen challenge further increase in sputum uPA (187 ± 144 pg/ml; p=0.03) and PAI-1 (6252 ± 2323 pg/ml; p<0.0001) concentrations were observed. Moreover, in Dp challenged, but not in saline challenged HDM-AAs the mean uPA/PAI-1 ratio decreased significantly at T24. No significant increase in the studied parameters were found in sham challenged patients. In HDM-AAs allergen exposure leads to activation of the plasmin system in the airways. Greater increase of the PAI-1 concentration than uPA concentration after allergen challenge may promote airway remodeling and play an important role in the development of bronchial hyperreactivity.

摘要

尿激酶型纤溶酶原激活剂(uPA)及其抑制剂(PAI-1)参与了与急慢性炎症相关的组织重塑和修复过程。本研究的目的是评估变应原激发对屋尘螨过敏性哮喘患者(HDM-AAs)诱导痰中uPA和PAI-1浓度的影响。本研究招募了30名HDM-AAs患者和10名健康人(HCs)。对24名HDM-AAs患者进行了支气管激发试验,用尘螨(Dp)进行激发,对6名HDM-AAs患者用生理盐水进行假激发试验。在HDM-AAs患者中,于激发前24小时(T0)和激发后24小时(T24)诱导痰液。采用免疫酶法测定诱导痰中uPA和PAI-1的浓度。在T0时,HDM-AAs患者痰液中uPA的平均浓度(151±96 pg/ml)和PAI-1的平均浓度(4341±1262 pg/ml)高于HCs(分别为18.8±6.7 pg/ml;p=0.0002和596±180 pg/ml;p<0.0001,uPA和PAI-1)。变应原激发后,痰液中uPA(187±144 pg/ml;p=0.03)和PAI-1(6252±2323 pg/ml;p<0.0001)的浓度进一步升高。此外,在Dp激发的HDM-AAs患者中,但在生理盐水激发的HDM-AAs患者中未观察到,T24时uPA/PAI-1平均比值显著降低。在假激发试验的患者中,未发现所研究参数有显著增加。在HDM-AAs患者中,变应原暴露导致气道中纤溶酶系统激活。变应原激发后PAI-1浓度的升高幅度大于uPA浓度,这可能促进气道重塑,并在支气管高反应性的发展中起重要作用。

相似文献

1
Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.变应原激发后哮喘患者诱导痰中纤溶酶原激活物抑制剂-1(PAI-1)和尿激酶型纤溶酶原激活物(uPA)的浓度。
Folia Histochem Cytobiol. 2010 Dec;48(4):518-23. doi: 10.2478/v10042-010-0075-2.
2
Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.过敏性哮喘患者痰液中的纤溶酶原激活物抑制剂-1(PAI-1)和尿激酶型纤溶酶原激活物(uPA)
Folia Histochem Cytobiol. 2008;46(2):193-8. doi: 10.2478/v10042-008-0029-0.
3
Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge.变应原激发试验期间过敏性哮喘患者血浆纤溶酶原激活物抑制剂-1的浓度
Int Arch Allergy Immunol. 2007;144(3):240-6. doi: 10.1159/000103998. Epub 2007 Jun 19.
4
The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients.屋尘螨敏感型过敏性哮喘患者中纤溶酶原激活物抑制剂-1启动子-675 4G/5G多态性
Allergy. 2006 Feb;61(2):234-8. doi: 10.1111/j.1398-9995.2005.00948.x.
5
Increase in allergen-specific IgE and ex vivo Th2 responses after a single bronchial challenge with house dust mite in allergic asthmatics.在过敏性哮喘患者单次支气管螨变应原挑战后,过敏原特异性 IgE 和体外 Th2 反应增加。
Allergy. 2012 Jan;67(1):67-73. doi: 10.1111/j.1398-9995.2011.02722.x. Epub 2011 Sep 29.
6
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.I期恶性黑色素瘤中的尿激酶型纤溶酶原激活物及1型和2型纤溶酶原激活物抑制剂
Oncol Rep. 2003 May-Jun;10(3):635-9.
7
The effect of allergen-induced bronchoconstriction on concentration of 5-oxo-ETE in exhaled breath condensate of house dust mite-allergic patients.屋尘螨变应原诱发支气管收缩对呼出气冷凝液中 5-氧二十碳三烯酸浓度的影响。
Clin Exp Allergy. 2017 Oct;47(10):1253-1262. doi: 10.1111/cea.12990. Epub 2017 Sep 15.
8
Early-life house dust mite allergens, childhood mite sensitization, and respiratory outcomes.早期生活中的尘螨过敏原、儿童时期的尘螨致敏以及呼吸道结局。
Allergy. 2015 Jul;70(7):820-7. doi: 10.1111/all.12626. Epub 2015 Apr 20.
9
IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators.IMD-4690是一种新型的纤溶酶原激活物抑制剂-1特异性抑制剂,通过调节血管生成和重塑相关介质,减轻慢性哮喘小鼠模型中的过敏性气道重塑。
PLoS One. 2015 Mar 18;10(3):e0121615. doi: 10.1371/journal.pone.0121615. eCollection 2015.
10
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.尿激酶型纤溶酶原激活物(uPA)和纤溶酶原激活物抑制剂1型(PAI-1)在子宫内膜癌预后中的作用。
Gynecol Oncol. 2008 Mar;108(3):569-76. doi: 10.1016/j.ygyno.2007.11.025. Epub 2008 Jan 28.

引用本文的文献

1
Derangement of cell cycle markers in peripheral blood mononuclear cells of asthmatic patients as a reliable biomarker for asthma control.哮喘患者外周血单个核细胞细胞周期标志物紊乱作为哮喘控制的可靠生物标志物。
Sci Rep. 2021 Jun 4;11(1):11873. doi: 10.1038/s41598-021-91087-5.
2
Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.纤溶酶原激活物抑制剂口服有效小分子抑制剂对哮喘的治疗潜力
Am J Physiol Lung Cell Mol Physiol. 2016 Feb 15;310(4):L328-36. doi: 10.1152/ajplung.00217.2015. Epub 2015 Dec 23.
3
Brain-Derived Neurotrophic Factor Expression in Asthma. Association with Severity and Type 2 Inflammatory Processes.
脑源性神经营养因子在哮喘中的表达。与严重程度及2型炎症过程的关联。
Am J Respir Cell Mol Biol. 2015 Dec;53(6):844-52. doi: 10.1165/rcmb.2015-0015OC.
4
IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators.IMD-4690是一种新型的纤溶酶原激活物抑制剂-1特异性抑制剂,通过调节血管生成和重塑相关介质,减轻慢性哮喘小鼠模型中的过敏性气道重塑。
PLoS One. 2015 Mar 18;10(3):e0121615. doi: 10.1371/journal.pone.0121615. eCollection 2015.
5
Expression analysis of asthma candidate genes during human and murine lung development.哮喘候选基因在人及鼠肺发育过程中的表达分析。
Respir Res. 2011 Jun 23;12(1):86. doi: 10.1186/1465-9921-12-86.